Expression of leucocyte adhesion molecules on 66 clinical neuroblastoma specimens
- 19 June 1991
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 48 (4) , 502-510
- https://doi.org/10.1002/ijc.2910480405
Abstract
LFA‐3, ICAM‐1, HLA.ABC and HLA.DR expression was analyzed on 66 neuroblastoma specimens. HLA.ABC was expressed on 26 specimens, HLA.DR on 2, LFA‐3 on 20 and ICAM‐1 on 10. HLA.ABC and LFA‐3 were positive on ganglioneuroblastoma or ganglioneuroma, but they were negative on neuroblastoma, independently of the clinical staging; HLA.ABC and LFA‐3 were induced in vivo by chemotherapy in parallel with tumoral cell differentiation, in both the primary and the metastases. The expression of ICAM‐1 was restricted to 5 of the 10 low‐grade stage‐1 or stage‐2 specimens, 1 stage‐3 specimen, and the primary tumors of 2 patients with stage‐4 disease, analyzed hence at diagnosis and after chemotherapy (4 specimens); metastatic cells obtained in 1 of these patients were negative. HLA.ABC and LFA‐3 expressed on both myc N‐negative and ‐positive specimens, whereas ICAM‐1 was restricted to MYCN‐negative specimens. LFA‐3 diffusely stained partially differentiated neuroblasts, Schwann cells and ganglion cells. The expression of HLA.ABC on differentiated neuroblasts varied from one sample to another and within the same tumor; Schwann cells were strongly positive, but ganglion cells were negative. In positive samples, ICAM‐1 was expressed on differentiated neuroblasts and Schwann cells, but negative on ganglion cells; however, most of the differentiated tumors were ICAM‐1‐negative, suggesting ICAM‐1 induction by unknown local signal. The 4 markers were negative on undifferentiated neuroblasts. The distribution of these 4 markers on clinical specimens was in agreement with their reactivity on fetal tissues, as well as with results obtained on neuroblastoma cell lines before and after in vitro treatment with IFN‐γ.Keywords
This publication has 26 references indexed in Scilit:
- Human melanoma cells with high susceptibility to cell‐mediated lysis can be identified on the basis of icam‐1 phenotype, vla profile and invasive abilityInternational Journal of Cancer, 1990
- Icam ‐ melanoma cells are relatively resistant to cd3‐mediated t‐cell lysisInternational Journal of Cancer, 1990
- Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinationsInternational Journal of Cancer, 1990
- Interleukin 2 Immunotherapy in Children with Neuroblastoma after High-Dose Chemotherapy and Autologous Bone Marrow TransplantationPediatric Hematology and Oncology, 1990
- Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocolsEuropean Journal of Cancer and Clinical Oncology, 1989
- The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-λ, tumor necrosis factor α, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentationJournal of Neuroimmunology, 1989
- A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 casesCancer Treatment Reviews, 1989
- Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cellsNature, 1989
- Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.The Journal of Experimental Medicine, 1988
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985